Viewpoints

PharmaShots Interview: TFF’s Dr. Dale Christensen Shares Insight on the Thin Film Freezing Technology

In an interview with PharmaShots, Dr. Dale Christensen, Ph.D., Director of Clinical Development at TFF Pharmaceuticals shared his views on the preliminary data from the P-I trial of inhalable tacrolimus powder formulation for Lung Transplant & its TFF technology Shots: TFF has developed an inhalable tacrolimus powder formulation that can be delivered directly to the …

PharmaShots Interview: TFF’s Dr. Dale Christensen Shares Insight on the Thin Film Freezing Technology Read More »

PharmaShots Interview: Recce Pharmaceuticals’ James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Infected Burn Wounds

In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds. Shots: The multiple patients have been dosed in P-I/II trial evaluates the effectiveness & safety of RECCE 327 in 30 patients …

PharmaShots Interview: Recce Pharmaceuticals’ James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Infected Burn Wounds Read More »

PharmaShots Interview: Portage Biotech’s Dr. Ian Walters Shares Insight on the Data of INT230-6 Presented at ASCO 2021

In an interview with PharmaShots, Dr. Ian Walters, CEO of Portage Biotech shared his views on the interim data from the P-II IT-01 trial evaluates the safety and efficacy of INT230-6 as both a monotherapy and in combination with pembrolizumab or ipilimumab in solid tumors Shots: The P-II IT-01 trial evaluates the safety & efficacy …

PharmaShots Interview: Portage Biotech’s Dr. Ian Walters Shares Insight on the Data of INT230-6 Presented at ASCO 2021 Read More »

Exclusive Interview with PharmaShots: Kelly Pokuta and April Kunze of Prime Therapeutics Share Insight on MedDrive, a Medical Drug Management Program

In an exclusive interview with PharmaShots, Kelly Pokuta, Vice President of Pharmaceutical Trade Relations, and April Kunze, Senior Director, Clinical Formulary Development & Trend Management Strategy at Prime therapeutics share their views on the MedDrive as a first-of-its-kind medical drug management program uniquely aligned with its Blue Plan clients. Shots: Prime introduced the first-of-its-kind medical …

Exclusive Interview with PharmaShots: Kelly Pokuta and April Kunze of Prime Therapeutics Share Insight on MedDrive, a Medical Drug Management Program Read More »

PharmaShots Interview: Abbott’s Michael Dale Shares Insight on the CE Mark for the Next-Generation Navitor TAVI System

In an interview with PharmaShots, Michael Dale, Senior Vice President of the Structural Heart division at Abbott shared his views on the Navitor’s approval in the EU for patients with severe aortic stenosis who are at high or extreme surgical risk for open-heart surgery. Shots: Abbott has received CE Mark approval for its latest-generation transcatheter …

PharmaShots Interview: Abbott’s Michael Dale Shares Insight on the CE Mark for the Next-Generation Navitor TAVI System Read More »

PharmaShots Interview: Saniona’s Rami Levin Shares Insight on Tesomet for Hypothalamic Obesity

In an interview with PharmaShots, Rami Levin, Chief Executive Officer at Saniona shared his views on the US FDA’s ODD to Tesomet for the treatment of hypothalamic obesity (HO) and discuss its role in the company’s continued pipeline progress. Shots: Saniona reported that the FDA has granted orphan drug designation to Tesomet for the treatment …

PharmaShots Interview: Saniona’s Rami Levin Shares Insight on Tesomet for Hypothalamic Obesity Read More »

ViewPoints Article: Over Prescribed Medications and its Impact

Introduction: “Over-prescription” is defined as the action of prescribing a drug or treatment in greater amount or on more occasions than necessary. Overprescribing, in general in health care, has been a subject of frequent study. For instance, research published in 2018 found that 46% of a half-million outpatient antibiotic prescriptions were written by clinicians without diagnoses of …

ViewPoints Article: Over Prescribed Medications and its Impact Read More »

PharmaShots Interview: Revolo’s Jonathan Rigby Shares Insights on the ‘1104 for Eosinophilic Esophagitis

In an interview with PharmaShots, Jonathan Rigby, Group Chief Executive Officer at Revolo Biotherapeutics shared his views on the unique mechanism of ‘1104 and discuss the plan of the company’s clinical studies. Shots: Revolo reported the US FDA’s approval to initiate a P-II clinical trial evaluating the safety and efficacy of ‘1104 in adults with …

PharmaShots Interview: Revolo’s Jonathan Rigby Shares Insights on the ‘1104 for Eosinophilic Esophagitis Read More »

PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insight About the New AGA Guidelines Recommending Stelara (Ustekinumab) as a First-Line Treatment Option in Crohn’s Disease

In an interview with PharmaShots, Andrew Greenspan, VP, Immunology Affairs at Janssen shared his views on the new AGA guidelines on the medical management of moderate-to-severe Crohn’s disease and also highlighted about Janssen’s efforts in improving the QoL of patients with CD The AGA guidelines assessed the overall benefit of each drug and also compared …

PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insight About the New AGA Guidelines Recommending Stelara (Ustekinumab) as a First-Line Treatment Option in Crohn’s Disease Read More »

PharmaShots Interview: Adaptimmune’s Dennis Williams Shares Insight About the Company’s Pathway to Bringing the First-Ever TCR T-Cell Therapy for Solid Tumors to Market

In an interview with PharmaShots, Dennis Williams, SVP Late-stage Development at Adaptimmune shared his views on the Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform and their pathway to bringing the first-ever TCR T-cell therapy for solid tumors to market along with an overview about their industry-leading T-cell therapy pipeline in solid tumors. …

PharmaShots Interview: Adaptimmune’s Dennis Williams Shares Insight About the Company’s Pathway to Bringing the First-Ever TCR T-Cell Therapy for Solid Tumors to Market Read More »

PharmaShots Interview: Kaia Health’s Konstantin Mehl Shares Insight on the Funding to Transform the Treatment for MSK and COPD

In an interview with PharmaShots, Konstantin Mehl, President, CEO, and Founder at Kaia Health shared his views on the grant of $75M Series C funding to expand clinical capabilities & transform the treatment path for musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care in the US and EU. Shots: The funding will extend the …

PharmaShots Interview: Kaia Health’s Konstantin Mehl Shares Insight on the Funding to Transform the Treatment for MSK and COPD Read More »

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data from UNIFI Study of Stelara Presented at ECCO

In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Disease Area Leader, Gastroenterology at Janssen Research & Development shared his views on the data regarding the safety & efficacy of Stelara (ustekinumab) for UC patients, including long-term symptomatic & corticosteroid-free remission rates from the UNIFI study. Shots: The P-III UNIFI study evaluates the safety …

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data from UNIFI Study of Stelara Presented at ECCO Read More »

PharmaShots Interview: Prime Therapeutics’ Kelly Pokuta and April Kunze Share Insight on Medical Drug Management Program

In an interview with PharmaShots, Kelly Pokuta, Vice President of Pharmaceutical Trade Relations, and April Kunze, Senior Director, Clinical Formulary Development & Trend Management Strategy at Prime therapeutics share their views on the MedDrive as a first-of-its-kind medical drug management program uniquely aligned with Blue Plan clients. Shots: Prime introduced the first-of-its-kind medical drug management …

PharmaShots Interview: Prime Therapeutics’ Kelly Pokuta and April Kunze Share Insight on Medical Drug Management Program Read More »

PharmaShots Interview: Xencor’s Bassil I. Dahiyat Shares Insight on the US FDA’s Approval of COVID-19 Antibody Treatment Leveraging its Technology

In an interview with PharmaShots, Dr. Bassil I. Dahiyat, President and CEO of Xencor shared his views on the company’s collaborations with BMS and its Xtend XmAb technology. He also shed light on the EUA of Sotrovimab for COVID-19. Shots: The FDA has granted EUA to Vir and GSK’s sotrovimab, which was engineered with Xencor’s …

PharmaShots Interview: Xencor’s Bassil I. Dahiyat Shares Insight on the US FDA’s Approval of COVID-19 Antibody Treatment Leveraging its Technology Read More »

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insight on the Data of Taltz and Olumiant Presented at EULAR 2021

In an interview with PharmaShots, Dr. Lotus Mallbris, M.D., Ph.D., Vice President of Immunology Development at Lilly shared her views on the abstracts demonstrating data on the use of Taltz and Olumiant in rheumatic diseases, including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) for Taltz, and rheumatoid arthritis (RA) for Olumiant.  Shots: Lilly reported that key data from Taltz (ixekizumab) & Olumiant (baricitinib) is highlighted at the …

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insight on the Data of Taltz and Olumiant Presented at EULAR 2021 Read More »

PharmaShots Interview: Guardant Health’s Justin Odegaard Shares Insight on the US FDA’s Approval of Guardant360 CDx for Amgen’s Lumakras

In an interview with PharmaShots, Justin Odegaard, Vice President of Clinical Development at Guardant Health shares his views on the Guardant360 CDx approval as the first & only liquid biopsy companion diagnostic for Amgen’s Lumakras (sotorasib) KRASG12C inhibitor for use in advanced NSCLC. Shots: Guardant Health received the US FDA’s approval for Guardant360 CDx liquid …

PharmaShots Interview: Guardant Health’s Justin Odegaard Shares Insight on the US FDA’s Approval of Guardant360 CDx for Amgen’s Lumakras Read More »

ViewPoints Interview: Astellas’ Dr. Andrew Krivoshik Shares Insights on P-II FAST Study of Zolbetuximab

In an interview with PharmaShots, Dr. Andrew Krivoshik, Senior Vice President and Oncology Therapeutic Area Head at Astellas, shared his views on the P-II FAST study result published in the journal Gastric Cancer and highlights the data published in Annals of Oncology. Shots: The data from P-II FAST study evaluating zolbetuximab + EOX in 1L …

ViewPoints Interview: Astellas’ Dr. Andrew Krivoshik Shares Insights on P-II FAST Study of Zolbetuximab Read More »

ViewPoints Article: Ethno-Pharma- An Emerging Sector

The Healthcare sector in 2021 is evolving to a greater extent owing to the initiatives and advancements taking place to futureproof the healthcare facilities from uncertain, unwanted, and deadly events like Covid-19. These advancements are happening while keeping the patients at the center with more focus on preventive and immune health.  Now while talking about …

ViewPoints Article: Ethno-Pharma- An Emerging Sector Read More »

ViewPoints Interview: BD’s Tony Ezell Shares Insights on the Collaboration with USATF to Provide COVID – 19 Testing for US Athletes

In an interview with PharmaShots, Tony Ezell, President, North America and Chief Marketing Officer, BD shares its agreement with the USA Track and Field team for COVID-19 testing for the Olympic Trials. Shots: BD’s partnership with USATF is part of the company’s commitment to helping get people back to their normal lives The BD Veritor …

ViewPoints Interview: BD’s Tony Ezell Shares Insights on the Collaboration with USATF to Provide COVID – 19 Testing for US Athletes Read More »

ViewPoints Interview: Myovant’s Dave Marek Shares Insights on the US FDA’s Approval of Myfembree in Uterine Fibroids

In an interview with PharmaShots, Dave Marek. CEO of Myovant shares insights on the US FDA’s approval of Myfembree (relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg) in Uterine Fibroids. Shots: The US FDA has approved Myovant & Pfizer’s Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as the first once-daily …

ViewPoints Interview: Myovant’s Dave Marek Shares Insights on the US FDA’s Approval of Myfembree in Uterine Fibroids Read More »

ViewPoints Interview: Janssen’s Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021

In an interview with PharmaShots, Mark Wildgust, VP of Global Medical Affairs, Oncology at Janssen, Dr. Paolo Ghia, Division of Experimental Oncology at Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele and Paul Barr, Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute at University of Rochester …

ViewPoints Interview: Janssen’s Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021 Read More »

ViewPoints Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs

In an interview with PharmaShots, Denis Corin, Chief Executive Officer and Chairman of the Board at Q BioMed share his views on the supply agreement for Strontium89 with the US Department of Defense and Veterans Affairs. Shots: BioMed has signed a 5-year agreement to commercially serve the US Department of Veterans Affairs (VA) and Department …

ViewPoints Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs Read More »

ViewPoints Interview: BeyondSpring’s Dr. Ramon Mohanlal Shares Insights on the Data of Triple Combo Plinabulin Presented at ASCO 2021

In an interview with PharmaShots, Ramon Mohanlal, M.D., Ph.D., MBA, Chief Medical Officer and Executive Vice President of Research and Development at BeyondSpring share his views on the data of triple combination regimen presented at ASCO and also shed light on the impact of plinabulin on SCLC. Shots: Plinabulin in combination with nivolumab and ipilimumab …

ViewPoints Interview: BeyondSpring’s Dr. Ramon Mohanlal Shares Insights on the Data of Triple Combo Plinabulin Presented at ASCO 2021 Read More »

ViewPoints Interview: NephroSant’s Dr. Minnie Sarwal Shares Insights on QSant and the Need for Precision Medicine in Kidney Health

In an interview with PharmaShots, Dr. Minnie Sarwal, CEO and Co-Founder of NephroSant shares her view on the QSant and how this urine test can improve outcomes for transplant patients. She also shed light on the need for precision therapies in kidney transplant care. Shots: NephroSant’s Qsant is a needle-free urine test that helps in …

ViewPoints Interview: NephroSant’s Dr. Minnie Sarwal Shares Insights on QSant and the Need for Precision Medicine in Kidney Health Read More »

ViewPoints Interview: Myovant’s Juan Camilo Arjona Ferreira Shares Insights on the Ryeqo

In an interview with PharmaShots, Myovant’s Juan Camilo Arjona Ferreira, MD, Chief Medical Officer of Myovant Sciences shares his views on the CHMP’s positive opinion for Ryeqo (Relugolix Combination Tablet). Shots: The CHMP has adopted positive opinion recommending approval of Ryeqo (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment …

ViewPoints Interview: Myovant’s Juan Camilo Arjona Ferreira Shares Insights on the Ryeqo Read More »

ViewPoints Interview: Janssen’s Jan Wehkamp and Icahn School of Medicine’s Dr. Bruce Sands Share Insights on the Data Presented at DDW 2021

In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader at Janssen, and Bruce Sands, Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine share their views on the data of Stelara and Tremfya presented at DDW 2021. Shots: Janssen presented the new data on Stelara (ustekinumab) …

ViewPoints Interview: Janssen’s Jan Wehkamp and Icahn School of Medicine’s Dr. Bruce Sands Share Insights on the Data Presented at DDW 2021 Read More »

ViewPoints Interview: Repertoire’s Andrea DiFabio Shares Insights on the Importance of Series B Funding

In an interview with PharmaShots, Andrea DiFabio, JD, Chief Legal and Administration Officer of Repertoire Immune Medicines shares her views on the importance of $189M series B funding and how it will support the company’s pipeline and manufacturing plans. Shots: The company reported the completion of a $189 million Series B financing. Founded by Flagship …

ViewPoints Interview: Repertoire’s Andrea DiFabio Shares Insights on the Importance of Series B Funding Read More »

ViewPoints Interview: n-Lorem Foundation’s Dr. Stanley T. Crooke Shares Insights on its Collaboration with Ultragenyx to Provide Personalized Medicines to Ultra-Rare Patients

In an interview with PharmaShots, Dr. Stanley T. Crooke, Founder, and Chief Executive Officer and Chairman of the Board at n-Lorem Foundation share his views on the collaboration with Ultragenyx. Shots: n-Lorem Foundation is the first & only foundation of its kind with a mission to provide life-saving treatments to patients who have diseases caused …

ViewPoints Interview: n-Lorem Foundation’s Dr. Stanley T. Crooke Shares Insights on its Collaboration with Ultragenyx to Provide Personalized Medicines to Ultra-Rare Patients Read More »

ViewPoints Interview: Organicell’s Dr. Maria Ines Mitrani Shares Insights on the Zofin for COVID-19

In an interview with PharmaShots, Mari Mitrani, Chief Science Officer of Organicell shares her views on the positive results from the first ten COVID-19 patients treated with Zofin in India. Shots: This initial trial is being conducted in conjunction with Organicell’s Indian partner, CWI India, which has entered into a product testing and distribution agreement …

ViewPoints Interview: Organicell’s Dr. Maria Ines Mitrani Shares Insights on the Zofin for COVID-19 Read More »

ViewPoints Interview: Albert Labs’ Dr. Malcolm Barratt-Johnson Shares Insights on Psychedelic-Assisted Therapies

In an interview with PharmaShots, Dr. Malcolm Barratt-Johnson, Chief Medical Officer of Albert Labs shared his views on the psychedelic’s therapies, the companies’ business model and your plans for scaling the psychedelics therapies. Shots: Albert Labs will be the first psychedelics company to use an accelerated pathway, known as RWE studies, to swiftly provide access …

ViewPoints Interview: Albert Labs’ Dr. Malcolm Barratt-Johnson Shares Insights on Psychedelic-Assisted Therapies Read More »

ViewPoints Interview: Apellis’s Federico Grossi Shares Insights on the Data in GA Presented at ARVO 2021

In an interview with PharmaShots, Apellis’ Chief Medical Officer, Federico Grossi shares his views on the data presented at ARVO 2021. The studies support AI analytics as a tool to distinctly measure disease activity well as the therapeutic effect in GA. Shots: Apellis presented five oral presentations from an AI collaboration with the Ophthalmic Imaging …

ViewPoints Interview: Apellis’s Federico Grossi Shares Insights on the Data in GA Presented at ARVO 2021 Read More »

ViewPoints Interview: GSK’s Mike Crichton Shares Insights on the Approval of Benlysta in Europe

In an interview with PharmaShots, Mike Crichton, Senior Vice President, Global Therapy Area Head, Specialty & Primary Care at GSK shares his views on the European Commission’s approval of Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN). Shots: The European Commission approved the expanded …

ViewPoints Interview: GSK’s Mike Crichton Shares Insights on the Approval of Benlysta in Europe Read More »

ViewPoints Interview: Maxwell Biosciences’ Dr. Gill Diamond and Joshua McClure Share Insights Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2

In an interview with PharmaShots, Dr. Gill Diamond, Scientific Advisory Board Member and Joshua McClure, CEO and Co-founder of Maxwell Biosciences share their views on the news findings of the company published in MDI that demonstrated that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2. Shots: The studies showed that …

ViewPoints Interview: Maxwell Biosciences’ Dr. Gill Diamond and Joshua McClure Share Insights Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2 Read More »

ViewPoints Interview: Daiichi Sankyo’s Ken Keller Shares Insights on NICE Recommendation for Enhertu in HER2 Positive Breast Cancer

In an interview with PharmaShots, Ken Keller, President and Chief Executive Officer at Daiichi Sankyo and Global Head of the Daiichi Sankyo Oncology Business shared his views on the NICE CDF recommendation for Enhertu in unresectable or metastatic HER2 positive breast cancer and the company’s growth and pipeline. Shots: The recommendation from NICE is based on …

ViewPoints Interview: Daiichi Sankyo’s Ken Keller Shares Insights on NICE Recommendation for Enhertu in HER2 Positive Breast Cancer Read More »

ViewPoints Interview: Aurinia’s Neil Solomons Shares Insights on the Lupkynis

In an interview with PharmaShots, Neil Solomons, Co-founder and Chief Medical Officer of Aurinia shared his views on the data of Lupkynis (voclosporin) presented at the National Kidney Foundation 2021 Spring Clinical Meetings. Shots: New data analysis from the AURORA and AURA clinical studies shows that Aurinia’s therapy demonstrated efficacy across all LN biopsy classes. These data …

ViewPoints Interview: Aurinia’s Neil Solomons Shares Insights on the Lupkynis Read More »

ViewPoints Interview: Abbott’s Neil Moat Shares Insights on the Next Generation TriClip Transcatheter Tricuspid Valve Repair System

In an interview with PharmaShots, Neil Moat, M.D., Chief Medical Officer of Abbott’s Structural Heart Business shares his views on the CE mark approval of first-of-its-kind TriClip device. Shots: The new iteration of the device, called TriClip G4, offers new clip sizes and an enhanced leaflet grasping feature for physicians to further customize treatment to …

ViewPoints Interview: Abbott’s Neil Moat Shares Insights on the Next Generation TriClip Transcatheter Tricuspid Valve Repair System Read More »

ViewPoints Article: Recent Insights into Advances of COVID-19 Treatment

Introduction: The current century has witnessed the universal spread of the unknown species of coronaviruses. The rapid deterioration of the public health system with changes in ecology and urbanization has accelerated more recurrent epidemics, which become more troublesome to prevent and contain promptly. A novel coronavirus (CoV) emerged in December 2019, is associated with respiratory …

ViewPoints Article: Recent Insights into Advances of COVID-19 Treatment Read More »

ViewPoints Interview: Medicenna’s Dr. Fahar Merchant Shares Insights on the Bispecific Superkines

In an interview with PharmaShots, Dr. Fahar Merchant, CEO of Medicenna shares his views on the data of a new type of interleukin called bispecific Superkines, presented at AACR 2021   Shots: Bispecific Superkines can attack cold tumors, weakening the protection given to it by the tumor microenvironment and revealing it to the immune system …

ViewPoints Interview: Medicenna’s Dr. Fahar Merchant Shares Insights on the Bispecific Superkines Read More »

ViewPoints Interview: Medidata’s Anthony Costello Shares Insights on the Transformative Sensor Cloud Platform for Connected Devices and Wearable Sensors in Clinical Trials

In an interview with PharmaShots, Anthony Costello, President, Patient Cloud at Medidata share his views on the launch of Sensor Cloud which is a transformative platform for managing a sensor and digital health technology data during the clinical trials. Shots: The company launches Sensor Cloud for managing sensor and digital health technology data during the …

ViewPoints Interview: Medidata’s Anthony Costello Shares Insights on the Transformative Sensor Cloud Platform for Connected Devices and Wearable Sensors in Clinical Trials Read More »

ViewPoints Interview: Janssen’s Dr. Allitia DiBernardo Shares Insights on the Availability of Ponvory in the US

In an interview with PharmaShots, Dr. Allitia DiBernardo, Global Head of Medical Affairs for Neurology at the Janssen share her views on the availability of Ponvory in the US for MS patients. Shots: Ponvory offers patients superior efficacy in reducing annualized relapses and brain lesions over established oral therapy teriflunomide (Aubagio), with a safe and …

ViewPoints Interview: Janssen’s Dr. Allitia DiBernardo Shares Insights on the Availability of Ponvory in the US Read More »

Top 20 Medical Device Companies Based on 2020 Revenue

The medical devices industry is a fast-growing market driven by the complex needs of patients encouraging life science companies to develop innovative therapies to improve health and QoL In 2020, the companies have shown growth resulted from a rise in the number of healthcare facilities, healthcare expenditure, technological advancements. Medtronic remains at the top of …

Top 20 Medical Device Companies Based on 2020 Revenue Read More »

ViewPoints Interview: Entrada’s Dipal Doshi Shares Insights on the Series B Funding Utilize to Advance DMD Program into the Clinic

In an interview with PharmaShots, Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics share his views on $116M Series B financing and what does this milestone means for the company’s pipeline. Shots: The Series B financing was led by Wellington Management Company, who was joined by Redmile Group, TCG Crossover, Greenspring Associates, Point72, …

ViewPoints Interview: Entrada’s Dipal Doshi Shares Insights on the Series B Funding Utilize to Advance DMD Program into the Clinic Read More »

ViewPoints Interview: GCCA’s Andrew Spiegel Share Insights on the Clear Your View Campaign

In an interview with PharmaShots, Andrew Spiegel, Executive Director of the Global Colon Cancer Association shares the details of the campaign and put colors on the impact of complete biomarker testing for advanced CRC patients. Shots: The Clear Your View campaign is an awareness initiative sponsored by Guardant Health to raise awareness of the importance …

ViewPoints Interview: GCCA’s Andrew Spiegel Share Insights on the Clear Your View Campaign Read More »

ViewPoints Interview: Women First Digital’s Sneha Nair and Claire Crossett Share Insights on the Launch of World’s First Abortion Virtual Assistant, Ally on WhatsApp

In an interview with PharmaShots, Sneha Nair, Global Communications Officer at Women First Digital, and Claire Crossett at Assistant Director share insight on the launch of the world’s first-ever abortion virtual assistant, Ally, on WhatsApp in celebration of World Health Day’s 2021 theme: Building a fairer, healthier world. Shots: Ally, the HowToUse chatbot, is equipped …

ViewPoints Interview: Women First Digital’s Sneha Nair and Claire Crossett Share Insights on the Launch of World’s First Abortion Virtual Assistant, Ally on WhatsApp Read More »

ViewPoints Interview: Ipsen’s Dr. Med. Steven Hildemann Shares Insight on the EC’s Approval of Cabometyx + Nivolumab for Advanced Renal Cell Carcinoma

In an interview with PharmaShots, Prof. Dr. Med. Steven Hildemann, Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs, and Patient Safety of Ipsen share his views on the approval of the combination regimen for aRCC. He also shed light on the company’s near-term goals in the coming years. Shots: The EC approval …

ViewPoints Interview: Ipsen’s Dr. Med. Steven Hildemann Shares Insight on the EC’s Approval of Cabometyx + Nivolumab for Advanced Renal Cell Carcinoma Read More »

ViewPoints Interview: Aceto’s Gilles Cottier Shares Insight on the Acquisition of A&C and IsleChem

In an interview with PharmaShots, Gilles Cottier, Chief Executive Officer of Aceto shared his views on the acquisitions of A&C and IsleChem to highlight the company’s growth strategy. Shots: The acquisition of IsleChem has allowed the company to expand its manufacturing expertise in the US. Aceto currently has diversified access to a robust global supply …

ViewPoints Interview: Aceto’s Gilles Cottier Shares Insight on the Acquisition of A&C and IsleChem Read More »

ViewPoints Interview: Amolyt Pharma’s Thierry Abribat Shares Insight on AZP-3601 for Hypoparathyroidism

In an interview with PharmaShots, Thierry Abribat, Founder and Chief Executive Officer of Amolyt Pharma share his views on the clinical profile of AZP-3601. He also shed light on how it differs from other treatments in development for hypoparathyroidism. Shots: Amolyt Pharma presented positive data from the single ascending dose (SAD) portion of its Ph1 …

ViewPoints Interview: Amolyt Pharma’s Thierry Abribat Shares Insight on AZP-3601 for Hypoparathyroidism Read More »

ViewPoints Interview: J&J’s Sven Sjovall & Dr. Mark Watt Share Insight on Nicorette’s Latest Digital Smoking Cessation Offering

In an interview with PharmaShots, Johnson & Johnson’s Sven Sjovall, Sr Director, R&D Site Lead and Global Smoking Cessation, and Dr. Mark Watt, Senior Director Medical Affairs and Clinical Research at Johnson & Johnson share their views on Nicorette’s latest digital smoking cessation offering and the science behind the QuickMist SmartTrack. They also shed some …

ViewPoints Interview: J&J’s Sven Sjovall & Dr. Mark Watt Share Insight on Nicorette’s Latest Digital Smoking Cessation Offering Read More »

ViewPoints Interview: Dr. Drew Falconer Shares Insights on the Abbott’s NeuroSphere Virtual Clinic

In an interview with PharmaShots, Dr. Drew Falconer, Neurologist and Director at Inova Parkinson’s and Movement Disorders Center in Fairfax, Va. shares insights on the first neurostimulation technology in US that allows patients to receive treatment from doctor without leaving home. Shots: Abbott launches NeuroSphere Virtual Clinic that allows patients to communicate with their physicians, …

ViewPoints Interview: Dr. Drew Falconer Shares Insights on the Abbott’s NeuroSphere Virtual Clinic Read More »

ViewPoints Interview: Dr. Robert Koenekoop Shares Insights on Stellar Study Evaluating ProQR’s QR-421a

In an interview with PharmaShots, Dr. Robert Koenekoop, MD, PhD, Professor of Pediatric Surgery, Human Genetics and Adult Ophthalmology at McGill University’s Montreal Children’s Hospital shared his views on the clinical data of the trial and shed light on how RNA therapies work in eye disorders? Shots: QR-421a demonstrated a concordant benefit in multiple measures …

ViewPoints Interview: Dr. Robert Koenekoop Shares Insights on Stellar Study Evaluating ProQR’s QR-421a Read More »

ViewPoints Article: Adjunctive Nutraceutical Therapies Supporting Immunity in COVID-19

Nutraceuticals such as active phytochemicals, functional foods, and dietary supplements have medicinal properties and a variety of health benefits. The Indian subcontinent has been renowned for a home to various medicinal plant species because of climate conditions. These medicinal plant species have a novel role in managing multiple illnesses, including viral respiratory diseases, through immune …

ViewPoints Article: Adjunctive Nutraceutical Therapies Supporting Immunity in COVID-19 Read More »

ViewPoints Interview: Zealand Pharma’s Emmanuel Dulac Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Adult Patients with Diabetes

In an interview with PharmaShots, Emmanuel Dulac, Pharm.D., Ph.D., President and CEO of Zealand Pharma shares insight on the US FDA’s approval of Zegalogue and its availability in both an auto-injector and a prefilled syringe in June 2021. He also highlighted the importance of approval for the company and patients with hypoglycemia.   Shots: The approval …

ViewPoints Interview: Zealand Pharma’s Emmanuel Dulac Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Adult Patients with Diabetes Read More »

ViewPoints Interview: Pyxis Oncology’s Dr. Lara S. Sullivan and Dr. Ronald Herbst Share Insights on the Importance of Series B Funding to Advance their Portfolio

In an interview with PharmaShots, Dr. Lara S. Sullivan, Chief Executive Officer, and Dr. Ronald Herbst, Chief Scientific Officer of Pyxis Oncology share insight on the importance of Series B funding and shed light on the company’s strategy and near-term goals. Shots: Pyxis Oncology reported that it raised $152M in a series B on the …

ViewPoints Interview: Pyxis Oncology’s Dr. Lara S. Sullivan and Dr. Ronald Herbst Share Insights on the Importance of Series B Funding to Advance their Portfolio Read More »

ViewPoints Interview: Artelo Bio’s Dr. Saoirse O’Sullivan Shares Insights on Synthetic Cannabinoid for Cancer Anorexia

In an interview with PharmaShots, Dr. Saoirse O’Sullivan, Ph.D., Scientific Advisor to Artelo Bio shares insights on new cannabinoids, their relevancy, and the other opportunities that can arise from modulating the ECS. Shots: The endocannabinoid system is a network of neurotransmitters and receptors throughout the body that can have a significant impact on improving human health …

ViewPoints Interview: Artelo Bio’s Dr. Saoirse O’Sullivan Shares Insights on Synthetic Cannabinoid for Cancer Anorexia Read More »

ViewPoints Interview: Codiak BioSciences’ Douglas E. Williams Shares Insight on the Potential of its Engineered Exosomes

In an interview with PharmaShots, Douglas E. Williams, Ph.D., President and Chief Executive Officer of Codiak BioSciences shares insights on the potential of engineered exosomes and the data presented at SITC 2020. Shots: Codiak demonstrated the potential of engineered exosomes –  extracellular vesicles that act like the body’s FedEx delivery trucks to carry messengers between …

ViewPoints Interview: Codiak BioSciences’ Douglas E. Williams Shares Insight on the Potential of its Engineered Exosomes Read More »

ViewPoints Interview: Biogen’s Monica Mann Shares Insight on Plegridy to Treat Multiple Sclerosis

In an interview with PharmaShots, Monica Mann, Head of Global Medical, Multiple Sclerosis at Biogen shares her views on the Plegridy and how it works on MS patients. She also shed light on the approval of the therapy in the US and EU. Shots: The approval of Plegridy (IM) by the EC and the US …

ViewPoints Interview: Biogen’s Monica Mann Shares Insight on Plegridy to Treat Multiple Sclerosis Read More »

ViewPoints Interview: ViiV Healthcare’s Dr. Kimberly Smith Shares Insight on the Data Presented at CROI 2021

In an interview with PharmaShots, Dr. Kimberly Smith, Head of Global Research and Medical Strategy at ViiV Healthcare shares insights on the clinical data of GSK3640254 (GSK’254) at CROI 2021. She also highlights the key points of P-IIIb ATLAS-2M study that provide further evidence for both the once-monthly and every 2-months dosing regimens of long-acting …

ViewPoints Interview: ViiV Healthcare’s Dr. Kimberly Smith Shares Insight on the Data Presented at CROI 2021 Read More »

ViewPoints Interview: Leap Therapeutic’s Douglas Onsi Shares Insight on its Lead Candidate, DKN-01

In an interview with PharmaShots, Douglas Onsi, CEO and President of Leap Therapeutics shares insights on the clinical data of DKN-01 along with its mechanism. He also highlights the company’s growth, plans, goal etc. Shots: DKK1 is a secreted protein that modulates cell signaling pathways known as the Wnt signaling pathways, as well as the …

ViewPoints Interview: Leap Therapeutic’s Douglas Onsi Shares Insight on its Lead Candidate, DKN-01 Read More »

ViewPoints Interview: Fluxergy’s Tej Patel Shares Insight on Multimodal Diagnostic System

In an interview with PharmaShots, Tej Patel, CEO of Fluxergy shared his views on Fluxergy’s CE Marking and how it will democratize healthcare while creating better clinical outcomes. Shots: Fluxergy’s One-hour COVID-19 test requires less than 2-3 minutes of hands-on time and provides lab-quality RT-PCR test results within an hour. The Fluxergy analyzer is a …

ViewPoints Interview: Fluxergy’s Tej Patel Shares Insight on Multimodal Diagnostic System Read More »

ViewPoints Interview: Aravive’ s Dr. Gail McIntyre Shares Insight on AVB-500 and its Potential Against ccRCC

In an interview with PharmaShots, Dr. Gail McIntyre, CEO of Aravive shared her views on the AVB-500, its potential against ccRCC, and the design of the clinical trial evaluating the therapy. He also shed light on epidemiology of Clear Cell Renal Cell Carcinoma. Shots: AVB-500 is being evaluated in ccRCC, has been tested in preclinical …

ViewPoints Interview: Aravive’ s Dr. Gail McIntyre Shares Insight on AVB-500 and its Potential Against ccRCC Read More »

ViewPoints Interview: Marc Meachem Shares Insight on the ViiV’s 2021 Commitment to the Community

In an interview with PharmaShots, Marc Meachem, Head of US External Affairs at ViiV Healthcare shared his views on the company’s approach towards the community. He also shed light on the grants and funding received for the betterment of HIV patients. Shots: ViiV Healthcare is doubling its community investments in 2021 with the goal of …

ViewPoints Interview: Marc Meachem Shares Insight on the ViiV’s 2021 Commitment to the Community Read More »

ViewPoints Interview: NeuBase Therapeutics’ Dietrich Stephan Shares Insight on its Approach to Genetic Medicine

In an interview with PharmaShots, Dietrich Stephan, Ph.D., CEO of NeuBase Therapeutics shared his views on the importance of preclinical in vivo data for PATrOL-enabled anti-gene for myotonic dystrophy type 1. Shots: NeuBase announced in vitro and in vivo data for its DM1 program, demonstrating the potential of its genetic medicine platform to target the …

ViewPoints Interview: NeuBase Therapeutics’ Dietrich Stephan Shares Insight on its Approach to Genetic Medicine Read More »

ViewPoints Interview: Eli Lilly’s Marie Schiller Shares Insight on the Collaboration with Welldoc on New Version of BlueStar App

In an interview with PharmaShots, Marie Schiller Vice President of Product Development for Connected Care and Insulins at Lilly shared her views on its collaboration with Welldoc to integrate Welldoc’s insulin management technology into Lilly’s connected insulin solutions. Shots: Lilly and Welldoc are teaming up to create a new version of Welldoc’s BlueStar app which will be …

ViewPoints Interview: Eli Lilly’s Marie Schiller Shares Insight on the Collaboration with Welldoc on New Version of BlueStar App Read More »

ViewPoints Interview: Dr. Sezer, Peter C. Adamson and Israel Lowy Share Insight on the US FDA’s Approval of Libtayo (cemiplimab) in Patients with NSCLC with High PD-L1 Expression

Shots: In an interview with PharmaShots, Dr. Ahmet Sezer,  Sanofi’s Peter C. Adamson, and Regeneron’s Israel Lowy shared their views on the US FDA’s approval of Libtayo and the data supporting the approval. Regeneron and Sanofi received the US FDA’s approval for Libtayo for the 1L treatment of patients with advanced NSCLC whose tumors have …

ViewPoints Interview: Dr. Sezer, Peter C. Adamson and Israel Lowy Share Insight on the US FDA’s Approval of Libtayo (cemiplimab) in Patients with NSCLC with High PD-L1 Expression Read More »

ViewPoints Interview: Takeda’s Nirav Desai Shares Insight on Data of TAK-721 Presented at ACG 2021

In an interview with Nirav Desai, Global Clinical Development Lead at Takeda shared his views on Tak-721 presented at ACG 2021 and its implications for patients and HCPs. The presentation includes post hoc analyses from a 12-week, randomized, double-blind, placebo-controlled Phase 3 clinical trial that investigated the safety and efficacy of BOS in patients with EoE 11 to 55 …

ViewPoints Interview: Takeda’s Nirav Desai Shares Insight on Data of TAK-721 Presented at ACG 2021 Read More »

ViewPoints Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment

In an interview with PharmaShots, Dr. Todd D. Cohen, M.D., VP Medical Affairs and Medical Director of Urology at Myriad Genetics shared his views on the ability of a biomarker test to predict which men with aggressive prostate cancer will benefit from advanced hormonal therapy and which men with lower-risk prostate cancer can safely avoid such …

ViewPoints Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment Read More »

ViewPoints Interview: Fusion Pharma’s John Valliant Shares Insight on its Collaboration with AstraZeneca

In an interview with PharmaShots, John Valliant, CEO at Fusion Pharma shared his views on the company’s agreement with AstraZeneca, signed in Nov 2020. He also shared in-depth information about the company’s TATs platform & Fast-Clear linker technology and provide a glance at Fusion’s portfolio. Shots: Fusion to receive $5M up front and $40M as …

ViewPoints Interview: Fusion Pharma’s John Valliant Shares Insight on its Collaboration with AstraZeneca Read More »

ViewPoints Interview: SiO2’s Lawrence Ganti Shares Insight on the Efforts to Scale Up the Manufacturing of Vials for COVID-19 Vaccines

In an interview with PharmaShots, Lawrence Ganti, President & Chief Business Officer at SiO2 Materials Science shared his views on the efforts to scale up the manufacturing of vials to combat COVID-19. Additionally, he also shared the benefits of using SiO2’s smart vials and shed light on barrier technology. Shots: SiO2 received a $143M investment …

ViewPoints Interview: SiO2’s Lawrence Ganti Shares Insight on the Efforts to Scale Up the Manufacturing of Vials for COVID-19 Vaccines Read More »

ViewPoints Interview: Biogen’s Wildon R. Farwell Shares Insight on Phase 4 RESPOND Study of Spinraza

In an interview with PharmaShots, Wildon R. Farwell, M.D., MPH, Global Medical Head of Neuromuscular Diseases at Biogen shared his views on the P-IV RESPOND study that assesses the benefits of Spinraza in patients treated with Zolgensma. Shots: RESPOND is a two-year, open-label study to evaluate the efficacy and safety of Spinraza (nusinersen) in infants …

ViewPoints Interview: Biogen’s Wildon R. Farwell Shares Insight on Phase 4 RESPOND Study of Spinraza Read More »

ViewPoints Interview: Abbott’s Allen Burton Shares Insight on NeuroSphere myPath App

In an interview with PharmaShots, Allen Burton, M.D., Medical Director at Abbott Neuromodulation shared his views on the NeuroSphere myPath App which is designed to track and report pain relief in chronic pain patients. Shot: The app will record pain relief during the device trial period with SCS or DRG therapy, simplifying reporting outcomes & …

ViewPoints Interview: Abbott’s Allen Burton Shares Insight on NeuroSphere myPath App Read More »

ViewPoints Interview: ViiV Healthcare’s Max Laitaillade Shares Insight on Rukobia

In an interview with PharmaShots, Max Laitaillade, Vice President, Head of Global Research Strategy, ViiV Healthcare shared his views on the development of Rukobia and the story of its development. He also shed light on what this approval means to the patients. Shots: MA for Rukobia marks a critical breakthrough for this select group of …

ViewPoints Interview: ViiV Healthcare’s Max Laitaillade Shares Insight on Rukobia Read More »

ViewPoints Interview: Merz Aesthetics’ Dr. Terri Phillips Shares Insight on GP Campaign for Xeomin

In an interview with PharmaShots, Dr. Terri Phillips, Chief Medical Affairs Officer at Merz Aesthetics shared her views on the new campaign with Gwyneth Paltrow for its flagship product Xeomin. She also shed light on Medical Aesthetic treatments during the pandemic and how Merz is working to meet the demand. Shots: Merz Aesthetics collaborates with …

ViewPoints Interview: Merz Aesthetics’ Dr. Terri Phillips Shares Insight on GP Campaign for Xeomin Read More »

ViewPoints Interview: Lumen’s Brian Finrow Shares Insight on Need for the Cheaper Methods to Engineer Antibodies as a Treatment for COVID-19

In an interview with PharmaShots, Brian Finrow, Co-Founder and CEO of Lumen Bioscience shared his views on the critical need for a scalable and cheaper method to engineer antibodies as a potential treatment for Covid-19. He also shed light on why it is time for the industry to reevaluate plant-based biologics manufacturing as a possible …

ViewPoints Interview: Lumen’s Brian Finrow Shares Insight on Need for the Cheaper Methods to Engineer Antibodies as a Treatment for COVID-19 Read More »

ViewPoints Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen, the First Treatment for Leber Congenital Amaurosis 10 (LCA10)

In an interview with PharmaShots, Daniel A. de Boer of ProQR shared his views on P-II/III pivotal trial of Sepofarsen to treat the root cause of a rare eye disease, Leber congenital amaurosis 10 (LCA10) Shots: The Illuminate P-II/III trial of sepofarsen is a double-masked, randomized, controlled, multiple-dose study to evaluate if sepofarsen is effective …

ViewPoints Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen, the First Treatment for Leber Congenital Amaurosis 10 (LCA10) Read More »

ViewPoints Interview: PGDx’s Megan Bailey Shares Insight on the Partnership with QIAGEN and Almac

In an interview with PharmaShots, Megan Bailey, CEO of PGDx shared her views on PGDx’s collaboration with QIAGEN and Almac to advance cancer diagnostics and make precision medicine more accessible to healthcare systems, laboratories, and patients globally. Shots: On Jan 11, 2021, PGDx and Almac collaborated to enhance patient care in the oncology On Jan …

ViewPoints Interview: PGDx’s Megan Bailey Shares Insight on the Partnership with QIAGEN and Almac Read More »

ViewPoints Interview: ViiV Healthcare’s Dr. Kimberly Smith Shares Insight on Davato (dolutegravir/lamivudine)

In an interview with PharmaShots, Dr. Kimberly Smith, Head of Research & Development, ViiV Healthcare shed light on the FDA’s approval and the 3yrs. data of Dovato. Shots: Dovato (dolutegravir/lamivudine) is the first complete, once-daily, single-tablet, 2DR for the treatment of HIV-1 infection in both treatment-naïve and virologically suppressed adults In July 2020, the FDA …

ViewPoints Interview: ViiV Healthcare’s Dr. Kimberly Smith Shares Insight on Davato (dolutegravir/lamivudine) Read More »

ViewPoints Interview: Adagio Therapeutics’ Tillman Gerngross Shares Insight on the Development of Antibodies to Prevent COVID-19

In an interview with PharmaShots, Tillman Gerngross, Ph.D., Co-Founder, and CEO of Adagio Therapeutics shed light on the pre-clinical data of ADG2 and how it works on SARS-CoV-2. Shots: ADG2 showed broad and potent neutralizing activity against SARS-CoV and two SARS-related coronaviruses currently known to be circulating in bat populations (WIV-1 and SHC014) The company …

ViewPoints Interview: Adagio Therapeutics’ Tillman Gerngross Shares Insight on the Development of Antibodies to Prevent COVID-19 Read More »

ViewPoints Interview: Legend’s Ying Huang Shares Insight on ASH 2020 Data and Initiation of BLA Rolling Submission for Cilta-cel

In an interview with PharmaShots, Ying Huang, Ph.D., CEO and CFO of Legend Biotech shed light on the clinical data following the rolling submission of BLA for Cilta-cel. He also shared insight on Legends’ collaboration with Janssen. Shots: The submission of BLA was based on results from the P-Ib/II CARTITUDE-1 study of cilta-cel, which were …

ViewPoints Interview: Legend’s Ying Huang Shares Insight on ASH 2020 Data and Initiation of BLA Rolling Submission for Cilta-cel Read More »

ViewPoints Interview: GSK’s Steve Bradford Shares Insight on Benlysta

In an interview with PharmaShot, Steve Bradford, Vice President, Medicines Commercialization Leader at GSK shed light on the US FDA’s approval of Benlysta as the first and only approved treatment for both lupus and adult patients with active LN who are receiving standard therapy. Shots: The US FDA has approved GSK’s Benlysta (belimumab) as the …

ViewPoints Interview: GSK’s Steve Bradford Shares Insight on Benlysta Read More »

ViewPoints Article: Role of Digital Technology in Improving Diagnosis

Machine Learning (ML) and Artificial Intelligence (AI) are used efficiently by many researchers and companies to overcome challenges for improving medical diagnostics. Insights on Diagnostic Errors Diagnostic related errors contribute to a significant number of complications and patient deaths. According to the authors of an article published in BMJ, in the US, diagnostic error claims …

ViewPoints Article: Role of Digital Technology in Improving Diagnosis Read More »

ViewPoints Interview: ALX Oncology’s Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework

In an interview with PharmaShot, Dr. Sophia Randolph, Chief Medical Officer of ALX Oncology shared her views on the ALX Oncology’s collaboration with Zymework for evaluating the combination with ALX148 and zanidatamab for patients with advanced HER2-expressing breast cancer and other HER2-expressing solid tumors. Shots: Zymeworks will conduct a P-Ib study to assess the safety …

ViewPoints Interview: ALX Oncology’s Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework Read More »

ViewPoints Interview: Deciphera’s Mathew L. Sherman Shares Insight on Data of QINLOCK and DCC-3014 Presented at CTOS 2020

In an interview with PharmaShots, Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera shed light on encouraging preliminary results from the ongoing P-I/II study of DCC-3014 in TGCT patients and also presented the data of QINLOCK at CTOS 2020 Shots: Deciphera presented encouraging preliminary results from the ongoing Phase 1/2 …

ViewPoints Interview: Deciphera’s Mathew L. Sherman Shares Insight on Data of QINLOCK and DCC-3014 Presented at CTOS 2020 Read More »

ViewPoints Interview: Zogenix’s Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

In an interview with PharmaShots, Bradley Galer, M.D., Chief Medical Officer at Zogenix shed light on data supporting the regulatory application and what the EU approval of Fintepla will mean in terms of reducing the high physical, emotional, and financial burden associated with the disease. Shots: Fintepla was approved by the EC in Dec’2020 as …

ViewPoints Interview: Zogenix’s Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution) Read More »

ViewPoints Interview: Medicago’s Nathalie Landry Shares Insight on Plant-Derived Vaccine for COVID-19

In an interview with PharmaShots, Nathalie Landry, Executive Vice President, Scientific and Medical Affairs at Medicago shared her views on positive results of P-I clinical trial results for its plant-derived COVID-19 vaccine.  Shots: The results of the trial demonstrated that 100% of participants developed a promising antibody response after two doses of Medicago’s COVID-19 adjuvanted …

ViewPoints Interview: Medicago’s Nathalie Landry Shares Insight on Plant-Derived Vaccine for COVID-19 Read More »

ViewPoints Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020

In an interview with PharmaShots, Dr. Andreas Harstrick, Chief Medical Officer at Affimed shared his views on updated clinical data related to their lead innate cell engager AFM13 at the virtual 62nd American Society of Hematology (ASH) annual meeting. Shots: The study showed an ORR of 42% (6/14 patients) and demonstrated clinical activity in two …

ViewPoints Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020 Read More »

ViewPoints Article: Wearables in the Market & their Roles

Wearables are electronic devices consisting of sensors that can receive data of user’s personal health and exercise schedules. They work wirelessly or with the help of other devices such as smartphones, tablets, or laptops. The market of wearable technology was valued at $15.74 billion in 2015 & expected to extend $51.60 billion by 2022 at …

ViewPoints Article: Wearables in the Market & their Roles Read More »

ViewPoints Interview: Tilak Healthcare’s Edouard Gasser Shares Insights on OdySight

In a recent interview with PharmaShots, Edouard Gasser, CEO of Tilak Healthcare shared his views on OdySight, which is the first medical game to monitor eyesight for patients with chronic eye diseases. Shots: OdySight is a free mobile game and medical-grade application used to remotely monitor patients suffering from chronic maculopathies such as AMD, macular …

ViewPoints Interview: Tilak Healthcare’s Edouard Gasser Shares Insights on OdySight Read More »

ViewPoints Interview: BoneHealth Technologies’ Laura Yecies Shares Insights on OsteoBoost Vibration Belt

In a recent interview with PharmaShots, Laura Yecies, CEO of BoneHealth Technologies shared her views on OsteoBoost Vibration Belt that has been granted “Breakthrough Device” designation by the US FDA Shots: OsteoBoost receives the US FDA’s BDD to reduce the risk of osteoporosis. It uses vibration technology that delivers mechanical stimulation to the hips & spine …

ViewPoints Interview: BoneHealth Technologies’ Laura Yecies Shares Insights on OsteoBoost Vibration Belt Read More »

ViewPoints Interview: BMS Foundation’s Patricia Mae Doykos Shares Insights on COVID Advocacy Exchange

In a recent interview with PharmaShots, Patricia Mae Doykos, Lead, Health Equity Initiative, and Director, BMS Foundation at Bristol Myers Squibb shared her views on the promotion of health equity and improvement in health outcomes of populations disproportionately affected by serious diseases and conditions. Shots: CAE is a virtual platform that convenes advocacy groups, patients, …

ViewPoints Interview: BMS Foundation’s Patricia Mae Doykos Shares Insights on COVID Advocacy Exchange Read More »

ViewPoints Interview: Enosi LifeSciences’ Dr. H. Michael Shepard Shares Insights on TNF-Inhibiting Molecules

In a recent interview with PharmaShots, Dr. H. Michael Shepard CEO and Co-Founder of Enosi shared his views on the announcement that Enosi Life Sciences has filed a patent for three of its TNF-inhibiting molecules: EN1001 for autoimmune disease, along with EN2001 and EN3001 for autoimmune disease and cancer. Shots: Enosi will offer use in …

ViewPoints Interview: Enosi LifeSciences’ Dr. H. Michael Shepard Shares Insights on TNF-Inhibiting Molecules Read More »

ViewPoints Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App

In a recent interview with PharmaShots, Jonas Duss, US CEO and Co-Founder at Kaia Health shared his views on the Kaia Health’s COPD Pulmonary Rehabilitation App and their collaboration with Chiesi Group to commercialize the app in EU. Shots: Kaia Health signs an exclusive agreement with Chiesi Group to commercialize the Kaia Health COPD Pulmonary …

ViewPoints Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App Read More »

ViewPoints Interview: Vigeo Therapeutics’ Dr. Lou Vaickus and Dr. Jing Watnick Share Insights on VT1021 Data Presented at SITC 2020

In a recent interview with PharmaShots, Dr. Jing Watnick, Co-Founder and Chief Executive Officer, and Dr. Lou Vaickus, Interim Chief Medical Officer at Vigeo shared their views on the data findings presented at the SITC 2020 Annual Meeting that demonstrated VT1021 as a single-agent has a favorable safety profile and shows early signals of clinical …

ViewPoints Interview: Vigeo Therapeutics’ Dr. Lou Vaickus and Dr. Jing Watnick Share Insights on VT1021 Data Presented at SITC 2020 Read More »

ViewPoints Interview: Janssen’s Kiran Patel Shares Insights on Amivantamab for Metastatic EGFR Exon 20+ NSCLC

In a recent interview with PharmaShots, Kiran Patel, Vice President Clinical Development, Solid Tumor Franchise at Janssen shared his views on the regulatory submission of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Shots: Janssen reported the BLA submission to the US FDA seeking approval …

ViewPoints Interview: Janssen’s Kiran Patel Shares Insights on Amivantamab for Metastatic EGFR Exon 20+ NSCLC Read More »

ViewPoints Interview: Janssen’s Andrew Greenspan Shares Insights on the Data Presented at ACR2020

In a recent interview with PharmaShots, Andrew Greenspan, MD, VP Medical Affairs of Janssen Immunology shared his views on Janssen’s commitment to advance research in rheumatic disease. Shots: Janssen presented clinical trial results in 35 abstracts featuring findings across PsA, RA, and SLE at ACR Convergence 2020 Virtual Scientific Program Sixteen abstracts focus on Tremfya …

ViewPoints Interview: Janssen’s Andrew Greenspan Shares Insights on the Data Presented at ACR2020 Read More »

ViewPoints Interview: GSK’s Dr. Riju Ray Shares Insights on the Role of Community-Based Pulmonologists in Improving COPD Management Among PCPs

In a recent interview with PharmaShots, Dr. Riju Ray, MD, PhD, Senior Medical Lead at GSK, leading US medical affairs across asthma and COPD shared his views on how community-based pulmonologists are improving COPD management and education among referring PCPs. Shots: Pulmonologists identified 12 strong to moderate predictors of future COPD exacerbations, some of which …

ViewPoints Interview: GSK’s Dr. Riju Ray Shares Insights on the Role of Community-Based Pulmonologists in Improving COPD Management Among PCPs Read More »

ViewPoints Interview: Genentech’s Ted Omachi Shares Insight on the US FDA’s Approval of Xolair in Nasal polyps

In a recent interview with PharmaShots, Ted Omachi, Global Development Leader for Xolair, and Senior Medical Director of Product Development for Immunology, Genentech shared his views on the approval of Xolair in the US. Shots: The approval is based on P-III POLYP 1 & 2 trials assessing Xolair vs PBO in 138 & 127 adult …

ViewPoints Interview: Genentech’s Ted Omachi Shares Insight on the US FDA’s Approval of Xolair in Nasal polyps Read More »

ViewPoints Article: 3D Bioprinting Represents a Huge Leap in the Pharmaceutical Industry

Three-dimensional technology has been an integral part of the pharmaceutical industry for many years. The medical fraternity has witnessed the clinical benefits of 3D technology such as printed anatomical prostheses, heart valves, biological tissues, hearing aids, and much more. The global 3D printed drugs market was valued at US$ 29 million in 2019 and is …

ViewPoints Article: 3D Bioprinting Represents a Huge Leap in the Pharmaceutical Industry Read More »

ViewPoints Interview: ViiV Healthcare’s Kimberly Smith Shares Insight on Data of Long-Acting Cabotegravir and Rilpivirine Presented at IDWeek 2020

In a recent interview with PharmaShots, Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare shared information on the positive findings presented at the 2020 Infectious Diseases Society of America (IDWeek) and the impact of COVID-19 on the development of long-acting cabotegravir and rilpivirine. Shots: The company reported the positive findings of …

ViewPoints Interview: ViiV Healthcare’s Kimberly Smith Shares Insight on Data of Long-Acting Cabotegravir and Rilpivirine Presented at IDWeek 2020 Read More »

ViewPoints Interview: Neoleukin’s Daniel-Adriano Silva Shares Insight on Novel Protein Designed to Treat or Block SARS-COV-2

In a recent interview with PharmaShots Daniel-Adriano Silva, PhD, Co-founder and Vice President Head of Research at Neoleukin shared the significance and promise of the findings published in Science and discuss the details of its De Novo Protein Design Shots: NL-CVX1 (CTC-445.2d) demonstrated the ability to prevent infection of multiple human cell lines in vitro and …

ViewPoints Interview: Neoleukin’s Daniel-Adriano Silva Shares Insight on Novel Protein Designed to Treat or Block SARS-COV-2 Read More »

ViewPoints Interview: Kezar’ Noreen Henig Shares Insight on Therapeutic Potential of KZR-616

In a recent interview with PharmaShots, Noreen Henig, Chief Medical Officer at Kezar Life Sciences shared information on clinical and pre-clinical data supporting the potential of KZR-616 to positively affect multiple drivers of immune-mediated diseases. Shots: The poster presented at ACR 2020 includes additional patient-weeks of safety and tolerability data compared to prior data presentations …

ViewPoints Interview: Kezar’ Noreen Henig Shares Insight on Therapeutic Potential of KZR-616 Read More »

ViewPoints Article: Digital Biomarkers

The Healthcare industry is going through a technological revolution and it is vital for the industry to work on new technologies that will help to generate, collect & track novel data. The availability of large data makes the system becomes important to convert it into appropriate information which will helps industry researchers, clinicians, doctors, entrepreneurs, …

ViewPoints Article: Digital Biomarkers Read More »

ViewPoints Interview: Cellares’ Fabian Gerlighaus Shares Insight on Cell Shuttle

In a recent interview with PharmaShots, Fabian Gerlighaus, Co-Founder and CEO of Cellares, shared information on Cellares partnership with Fred Hutchinson Cancer Research Center and unveils how the company is working to get patients the cell therapies they need. Shots: Cellares’ collaboration with Fred Hutchinson Cancer Research Center is a part of EAPP. Fred Hutch …

ViewPoints Interview: Cellares’ Fabian Gerlighaus Shares Insight on Cell Shuttle Read More »

ViewPoints Interview: Novocure’s William F. Doyle Shares Insight on Company’s Accomplishments in the Treatment of Glioblastoma and Mesothelioma

In a recent interview with PharmaShots, William F. Doyle, Executive Chairman at Novocure shared information about the company’s activities in the field of glioblastoma and mesothelioma. He also discussed the company’s technology, Tumor Treating Fields (TTFields), and its potential for broad applicability across solid tumors. Shots: Novocure is a global oncology company working to extend …

ViewPoints Interview: Novocure’s William F. Doyle Shares Insight on Company’s Accomplishments in the Treatment of Glioblastoma and Mesothelioma Read More »

ViewPoints Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM

In a recent interview with PharmaShots, Julie Foster, Vice President, Global Customer Experience of the Diabetes business at Medtronic, shares information about recent and upcoming announcements for the company. Shots: The integration of real-time CGM data into the smart insulin pen app follows the acquisition of Companion Medical’s InPen to the Medtronic portfolio, as of Sept’2020 The …

ViewPoints Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM Read More »

ViewPoints Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM

In a recent interview with PharmaShots, Julie Foster, Vice President, Global Customer Experience of the Diabetes business at Medtronic, shares information about recent and upcoming announcements for the company. Shots: The integration of real-time CGM data into the smart insulin pen app follows the acquisition of Companion Medical’s InPen to the Medtronic portfolio, as of Sept’2020 The …

ViewPoints Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM Read More »

ViewPoints Interview: Duke’s Andrea Taylor Shares Insight on Launch And Scale Speedometer

In a recent interview with PharmaShots, Andrea Taylor, Researcher at Launch And Scale Speedometer shared her insights and highlights on data how rich countries’ shopping spree for COVID-19 vaccines means fewer vaccinations for billions in low-income countries Shots: The Launch and Scale Speedometer project aims to systematically analyze the factors that support or hinder the …

ViewPoints Interview: Duke’s Andrea Taylor Shares Insight on Launch And Scale Speedometer Read More »

ViewPoints Interview: FibroGen’s Peony Yu Shares Insight on Roxadustat

In a recent interview with PharmaShots, Peony Yu, Chief Medical Officer of FibroGen shared her insights and highlights on data of Roxadustat Shots: FibroGen presented new efficacy and safety analyses from the roxadustat global P-III program at ASN Kidney Week 2020 Reimagined. FibroGen and its partners, AstraZeneca and Astellas, presented 42 abstracts, including 2 late-breaker …

ViewPoints Interview: FibroGen’s Peony Yu Shares Insight on Roxadustat Read More »

ViewPoints Interview: Caris Life Sciences’ Dr. Spetzler Shares Insight on AI-Powered Clinico-Genomic Data Platform

In a recent interview with PharmaShots, Dr. Spetzler, President and Chief Scientific Officer of Caris Life Sciences shared his insights and highlights on data of the launch of CODEai. Shots: CODEai is a real-world clinico-genomic data platform that integrates Caris Life Sciences’ extensive catalog of molecular data with cancer treatment information and clinical outcomes data …

ViewPoints Interview: Caris Life Sciences’ Dr. Spetzler Shares Insight on AI-Powered Clinico-Genomic Data Platform Read More »

ViewPoints Interview: True Digital Surgery’s Aidan Foley Shares Insight on Aesculap Aeos Robotic Digital Microscope

In a recent interview with PharmaShots, Aidan Foley, Chairman and Chief Operating Officer of True Digital Surgery share his insights and highlights on data of Aesculap Aeos Robotic Digital Microscope. Shots: The robotic digital microscope enables surgeons to execute precision movements in neurosurgery, spine, and ear, nose, and throat operations, through a multi-axis robotic arm. …

ViewPoints Interview: True Digital Surgery’s Aidan Foley Shares Insight on Aesculap Aeos Robotic Digital Microscope Read More »

ViewPoints Article: Organs on a chip (OOCs) – Transforming Animal Testing

Clinical studies cost money, time, and animal lives. There is an urgent need for alternative ways to model human diseases in-vitro to speed-up the new drug development process. Recently, Indian researchers have started exploring advanced technologies to replace animals in research. Organs on a chip (OOCs) is a novel concept, emerging as the next wave …

ViewPoints Article: Organs on a chip (OOCs) – Transforming Animal Testing Read More »

ViewPoints Interview: Neurocrine’s Dr. Eiry Roberts Shares Insight on Ongentys (opicapone)

In a recent interview with PharmaShots, Dr. Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences shares his insights and highlights on data of Ongentys. Shots: In a post-hoc, sub-group analysis of the P-III BIPARK-1 study demonstrated greater reductions in overnight “off” time and time to morning “on” time compared to entacapone in patients with PD …

ViewPoints Interview: Neurocrine’s Dr. Eiry Roberts Shares Insight on Ongentys (opicapone) Read More »

ViewPoints Interview: Dicerna’s Doug Fambrough Shares Insight on Nedosiran Data Presented at ASN Week 2020

In a recent interview with PharmaShots, Doug Fambrough, Ph.D., President and CEO of Dicerna shares his insights and highlights on data of Nedosiran presented at ASN Week 2020. Shots: All participants regardless of PH subtype, achieved normal or near-normal Uox excretion @day180, 92% participants (100% & 67% with PH1 & PH2) achieved normal Uox excretion …

ViewPoints Interview: Dicerna’s Doug Fambrough Shares Insight on Nedosiran Data Presented at ASN Week 2020 Read More »

ViewPoints Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Mirikizumab

In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Mirikizumab.  Shots: @52wks. ~60% achieved endoscopic responses (58.5% in IV dosing group and 58.7% in the SC group) while 45% + achieved PRO remission (46.3% in the IV group and 45.6% in the …

ViewPoints Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Mirikizumab Read More »

ViewPoints Interview: Takeda’s Andrea Stancati Shares Insights on Entyvio (vedolizumab) SC Formulation

In a recent interview with PharmaShots, Andrea Stancati, Vice President, Head GI Global Medical Franchise shares his insights and highlights of Entyvio (vedolizumab) Shots: The ongoing P-IIIb VISIBLE OLE study involves assessing of Entyvio (SC) in adult patients with UC or CD, following enrolment and participation in the VISIBLE 1 (UC) or VISIBLE 2 (CD) …

ViewPoints Interview: Takeda’s Andrea Stancati Shares Insights on Entyvio (vedolizumab) SC Formulation Read More »

ViewPoints Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep&amp Viral RNA UM Kit

In a recent interview with PharmaShots, Kai te Kaat, the Vice President, Head of Franchise Oncology, MDx at QIAGEN shares his insights and highlights on QIAprep&amp Viral RNA UM Kit. Shots: QIAGEN to launch the QIAprep&amp Viral RNA UM Kit, designed to simplify and accelerate PCR swab analysis and remove key testing bottlenecks for Covid-19 and other …

ViewPoints Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep&amp Viral RNA UM Kit Read More »

ViewPoints Article: Digital Healthcare in India – Current Trends & Future

Digital healthcare means using communications and information technologies in medicine to diagnose, predict, treat, and monitor diseases. It is also widely used for prognosis, rehabilitation, behavioral health, and public health.  Indians have witnessed a surge of smartphone and internet use since the last decade. This had led to an easier delivery of smart digital solutions. …

ViewPoints Article: Digital Healthcare in India – Current Trends & Future Read More »

ViewPoints: Medical Representative Opinion Survey for Business Continuity with New Normal

K. K. Consulting Services has conducted this survey by contacting around 2200 medical representatives accros the india uisng google forms. Objective of  The purpose of this survey is to design a platform for pharmaceutical sales professionals (PSP) to share their opinion about business continuity challenges faced by them due to the present COVID pandemic situation. …

ViewPoints: Medical Representative Opinion Survey for Business Continuity with New Normal Read More »

ViewPoints: COVID-19 Vaccine Distribution the Next Supply Chain Frontier

An overview of various aspects of the supply chain that would be crucial in the production and distribution of COVID-19 Vaccine. Write to us at connect@pharmashots.com if you want a PDF copy of this report. Over the past seven months, the global pandemic caused by the spread of SARS-CoV-2, the virus that leads to coronavirus …

ViewPoints: COVID-19 Vaccine Distribution the Next Supply Chain Frontier Read More »

PharmaShots ViewPoints: Revised approach for First Aid during and after the Catastrophic Pandemic – Safe and Saving

The SARS CoV-2 or COVID-19 pandemic has changed human life permanently. Hence, a few critical areas need revisiting in light of these changes to set a “new normal” for them. One of such areas is first aid. Correctly given first aid helps victim of an emergency episode of a disease or an accident prevents damage …

PharmaShots ViewPoints: Revised approach for First Aid during and after the Catastrophic Pandemic – Safe and Saving Read More »